Want to see PHVS full AI Analyst Report?
PHVS Stock Chart & Stats
$37.23
$0.91(2.74%)
At close: 4:00 PM EDT
$37.23
$0.91(2.74%)
Day’s Range― - ―
52-Week Range$20.65 - $38.13
Previous CloseN/A
Volume255.71K
Average Volume (3M)566.07K
Market Cap
$2.46B
Enterprise Value$1.99K
Total Cash (Recent Filing)$318.28M
Total Debt (Recent Filing)$673.73K
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Nov 18, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding69,863,686
10 Day Avg. Volume534,630
30 Day Avg. Volume566,071
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$48.78Price Target Upside31.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical And Regulatory ProgressFDA review and EMA application validation move deucrictibant closer to potential commercialization. Progress across on-demand and prophylactic indications could support a broader HAE franchise if Phase 3 results and regulatory reviews remain favorable.
Extended Cash RunwayA substantial cash balance and runway into 2028 provide funding for pivotal trials, regulatory work and pre-commercial preparation. This reduces near-term financing pressure and allows management to advance the pipeline through important value-creating milestones.
Low Financial LeverageExtremely low debt limits interest obligations and refinancing risk while preserving financial flexibility. Although the company is loss-making, its capital structure is not burdened by leverage, allowing available resources to remain focused on clinical development.
Bears Say
No Commercial RevenueThe absence of marketed products means Pharvaris has no recurring operating revenue to fund research, regulatory activity or commercialization. Its business model remains dependent on successful development and approval of deucrictibant before meaningful product sales can begin.
Persistent And Worsening Cash BurnLarge, recurring cash outflows indicate that operations currently consume substantial capital without internally generated funding. Continued trial and pre-commercial spending could require additional financing over time, creating execution and capital-allocation constraints.
Dependence On Clinical And Regulatory ExecutionThe company’s future value and eventual revenue depend heavily on pivotal efficacy and safety results plus regulatory approvals. Delays, unfavorable data or approval restrictions could postpone commercialization and extend losses, while the recent equity offering highlights ongoing funding needs.
Pharvaris News
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $20.65 and its highest was $38.13 in the past 12 months.
What is Pharvaris’s market cap?
Pharvaris’s market cap is $2.46B.
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Nov 18, 2026 which is in 72 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Aug 12, 2026. The company reported -$0.813 earnings per share for the quarter, missing the consensus estimate of -$0.759 by -$0.053.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate is -0.84.
How many shares outstanding does Pharvaris have?
Pharvaris has 69,863,686 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -$0.813 in its last earnings report, missing expectations of -$0.759. Following the earnings report the stock price went up 5.927%.
Which hedge fund is a major shareholder of Pharvaris?
Currently, no hedge funds are holding shares in PHVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharvaris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.78 (31.02% Upside)
$48.78 (31.02% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 81.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $82.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
52.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pharvaris
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
PHVS Stock 12 Month Forecast
Average Price Target
$48.78
▲(31.02% Upside)
Technical Analysis
Ownership Overview
2.71% Insiders
7.58% Mutual Funds
69.15% Other Institutional Investors
19.33% Public Companies and
Individual Investors